Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00030537 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: erlotinib hydrochloride

Sponsor

National Cancer Institute (NCI)